Evidence map›Paper›PMID 40160607›Full record

ArticleQuantitative imaging in medicine and surgery2025

Integration of PET/CT parameters and a clinical variable to predict the risk of progression of disease within 24 months (POD24) in follicular lymphoma.

Qiuhui Jiang, Zhijuan Lin, Qinwei Chen, Feng Lin, Chong Jiang, Manman Deng, Jie Zha, Long Liu, Chongyang Ding, Bing Xu

Erratum issuedAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Quantitative imaging in medicine and surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors.

Qiuhui Jiang *Department of Hematology, the First Affiliated Hospital of Xiamen University and Institute of Hematology, School of Medicine, Xiamen University, Xiamen, China.ORCID https://orcid.org/0000-0002-2613-706X
Zhijuan Lin *Department of Hematology, the First Affiliated Hospital of Xiamen University and Institute of Hematology, School of Medicine, Xiamen University, Xiamen, China.
Qinwei ChenDepartment of Hematology, the First Affiliated Hospital of Xiamen University and Institute of Hematology, School of Medicine, Xiamen University, Xiamen, China.
Feng LinDepartment of Hematology, the First Affiliated Hospital of Xiamen University and Institute of Hematology, School of Medicine, Xiamen University, Xiamen, China.
Chong JiangDepartment of Nuclear Medicine, the West China Hospital of Sichuan University, Chengdu, China.
Manman DengDepartment of Hematology, the First Affiliated Hospital of Xiamen University and Institute of Hematology, School of Medicine, Xiamen University, Xiamen, China.
Jie ZhaDepartment of Hematology, the First Affiliated Hospital of Xiamen University and Institute of Hematology, School of Medicine, Xiamen University, Xiamen, China.
Long LiuDepartment of Hematology, the First Affiliated Hospital of Xiamen University and Institute of Hematology, School of Medicine, Xiamen University, Xiamen, China.
Chongyang DingDepartment of Nuclear Medicine, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Bing XuDepartment of Hematology, the First Affiliated Hospital of Xiamen University and Institute of Hematology, School of Medicine, Xiamen University, Xiamen, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Patients with follicular lymphoma (FL) who experience progression of disease within 24 months (POD24) of receiving first-line therapy had a significantly poorer prognosis than that without early progression. Due to the established prognostic relevance of positron emission tomography/computed tomography (PET/CT) parameters in FL and their clinical accessibility, we aimed to investigate the predictive role of PET/CT metabolism and dissemination parameters in POD24 for FL. Methods: The POD24 status of 155 patients who underwent PET/CT examinations at initial diagnosis was evaluated. Various baseline characteristics were collected, along with PET/CT-derived parameters, including the maximum tumor dissemination (Dmax), maximum standardized uptake (SUVmax) value, total metabolic tumor volume (TMTV), and total lesion glycolysis (TLG). A Cox proportional regression analysis was used to identify potential risk predictors of POD24. Receiver operating characteristic (ROC) curves were used to define the optimal cut-off values. Results: In our cohort, POD24 was observed in 21 (13.5%) FL patients. The univariate and multivariate Cox regression analyses revealed that elevated lactate dehydrogenase (LDH) was a significant predictor of POD24. Additionally, survival analyses based on the cut-off values showed that the risk of POD24 was significantly increased in patients with a Dmax >64.24 cm, SUVmax >11.23, TMTV >144.16 cm Conclusions: PET/CT parameters have prognostic value for POD24 in FL. The risk model, which combined PET/CT parameters with clinical indicators, could improve risk stratification and help guide therapeutic decisions.

Indexed as

Follicular lymphoma (FL)positron emission tomography/computed tomography (PET/CT)progression of disease within 24 months (POD24)

Identifiers

PMID40160607
PMCPMC11948388

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.